Lfa-3 as a vaccine adjuvant

Details Lfa-3 as a vaccine adjuvant Lfa-3 as a vaccine adjuvant

A - Human Necessities

61

K

A61K 39/39 (2006.01) A61K 39/29 (2006.01) A61K 39/395 (2006.01) C07K 14/705 (2006.01)

Patent

CA 2049931

2049931 9111194 PCTABS00006 Vaccines comprising an immunogen and, as an adjuvant, LFA-3 or a fragment of LFA-3 capable of binding to CD2, a surface receptor on T-lymphocytes, are disclosed. LFA-3 has been found to markedly enhance the proliferation of activated T-cells and thus is capable of augmenting the immune response. Methods of vaccination in which LFA-3 is employed in conjunction with an immunogenic inoculum are also disclosed.

Affiliated with

Also associated with

Rating

Lfa-3 as a vaccine adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lfa-3 as a vaccine adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lfa-3 as a vaccine adjuvant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1366215